

Karen Akinsanya et al

Title:

LHRH ANALOGIES FOR THE TREATMENT OF

**OSTEOPOROSIS** 

Appl. No.:

09/830,343

Filing Date:

04/26/01

Examiner:

O. Chernyshev

Art Unit:

1646

TRANSMITTAL OF RESPONSE TO NOTICE TO COMPLY

Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Notice to Comply dated February 11, 2003, in which an extendible response is due by March 11, 2003, transmitted are:

[ X ] Return Copy of Notice to Comply;

A computer readable form (CFR) copy of the Sequence Listing; [X]

A paper copy of the Sequence Listing, [ X ]

A statement that the content of the substitute paper and CRF are [ X ] identical and, where applicable, include no new matter.

The Commissioner is hereby authorized to charge fees deficiency which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741.

Respectfully submitted,

**FOLEY & LARDNER** Washington Harbour 3000 K Street, N.W., Suite 500 Washington, D.C. 20007-5109

Telephone:

(202) 672-5404

Facsimile:

(202) 672-5399

Stephen A. Bent Attorney for Applicant Registration No. 29,768

	Application No.			
FEB 2 & 2003 Notice to Comply	Application No.	Applicant(s)	Applicant(s)	
	09/830,343 Examiner		AKINSANYA ET AL.	
		Art Unit		
NOTICE TO COMPLY WITH BEOLUDEMEN	Olga N. Chernyshev	1646		
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES				
Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to				
avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).				
The nucleotide and/or amino acid sequence disclosur for such a disclosure as set forth in 37 C.F.R. 1.821 -	e contained in this application	does not comply with		
1. This application clearly fails to comply with the directed to the final rulemaking notice published at the effective filing date is on or after July 1, 1998, 1998) and 1211 OG 82 (June 23, 1998).	t 55 FR 18230 (May 1, 1990).	and 1114 OG 20 (May	15 1000\ If	
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).				
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).				
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."				
5. The computer readable form that has been filed unreadable as indicated on the attached CRF Disk submitted as required by 37 C.F.R. 1.825(d).	with this application has bee tette Problem Report. A Subs	en found to be damaged stitute computer readab	l and/or le form must be	
☐ 6. The paper copy of the "Sequence Listing" is not as required by 37 C.F.R. 1.821(e).	the same as the computer re			
		REC	EIVED	
Applicant Must Provide:  ☑ An initial or substitute computer readable form (CR	F) copy of the "Sequence Lis	FEB	2.7 7003	
	e Listing", as well as an amen	dment directing its entr	NTER 1600/290 V into the	
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).				
For questions regarding compliance to these i	requirements, please cor	ntact:	•	
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-421 PatentIn Software Program Support	2			